Meropenem Trihydrate: Broad-Spectrum Carbapenem Antibiotic for Research

Executive Summary: Meropenem trihydrate is a broad-spectrum β-lactam antibiotic with high efficacy against clinically relevant gram-negative, gram-positive, and anaerobic bacteria under physiological pH conditions (APExBIO). It displays low MIC90 values for pathogens such as Escherichia coli and Klebsiella pneumoniae (pH 7.5). Its mechanism involves inhibition of penicillin-binding proteins, leading to rapid bacterial lysis (Dixon et al. 2025). Meropenem trihydrate is water-soluble (≥20.7 mg/mL, gentle warming) and remains stable at -20°C for short-term research workflows. In vivo models (e.g., acute necrotizing pancreatitis in rats) confirm its efficacy in reducing infection and tissue damage, especially when combined with adjuncts like deferoxamine. The product is intended for research use only and not for diagnostic or clinical applications.

Biological Rationale

Carbapenems, such as Meropenem trihydrate, are considered antibiotics of last resort for multidrug-resistant (MDR) bacterial infections (Dixon et al. 2025). They exhibit broad-spectrum activity, effectively targeting both gram-negative and gram-positive bacteria, including species producing extended-spectrum β-lactamases (ESBLs). The widespread emergence of carbapenemase-producing Enterobacterales (CPE) has increased the need for robust reference compounds in resistance and metabolomics research. Meropenem trihydrate’s low MIC90 values against key clinical isolates position it as an optimal agent for experimental infection models and mechanism-of-action studies. Its efficacy is modulated by environmental pH, with optimal antibacterial activity at physiological conditions (pH 7.5) (APExBIO).

Mechanism of Action of Meropenem trihydrate

Meropenem trihydrate acts by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), essential enzymes for peptidoglycan cross-linking in the bacterial cell wall. This binding disrupts cell wall integrity, resulting in osmotic lysis and bacterial death. Meropenem is resistant to most β-lactamases, including ESBLs and AmpC enzymes, due to its carbapenem core. Its efficacy is not affected by most outer membrane porin mutations in susceptible strains (Dixon et al. 2025). The compound does not exhibit significant activity against organisms with active carbapenemases or multidrug efflux pumps unless used in combination with inhibitors or adjuncts.

Evidence & Benchmarks

• Meropenem trihydrate displays low MIC90 values (≤0.25–2.0 μg/mL) for E. coli, K. pneumoniae, Enterobacter spp., and Streptococcus pneumoniae at pH 7.5 (APExBIO).
• Carbapenem resistance in Enterobacterales is primarily mediated by carbapenemase enzymes, efflux pumps, and porin loss; enzymatic hydrolysis is the dominant mechanism (Dixon et al. 2025).
• LC-MS/MS metabolomics can distinguish CPE from non-CPE isolates in under 7 hours using 21 metabolite biomarkers (AUROCs ≥ 0.845) (Dixon et al. 2025).
• In vivo, Meropenem trihydrate reduces pancreatic infection, hemorrhage, and fat necrosis in rat models of acute necrotizing pancreatitis, with enhanced effects when combined with deferoxamine (APExBIO).
• It is soluble in water (≥20.7 mg/mL, gentle warming) and DMSO (≥49.2 mg/mL), but insoluble in ethanol, facilitating diverse research protocols (APExBIO).

For a broader context on Meropenem trihydrate’s role in resistance modeling and metabolomics workflows, see "Meropenem Trihydrate: Broad-Spectrum Power for Resistance…". This article updates the previous review by integrating recent metabolomic biomarker findings and practical solubility benchmarks.

Applications, Limits & Misconceptions

Meropenem trihydrate is used extensively in:

• Antibacterial susceptibility testing against gram-negative, gram-positive, and anaerobic bacteria.
• Metabolomics-based resistance phenotyping and biomarker discovery (Dixon et al. 2025).
• Acute infection modeling in vivo, such as necrotizing pancreatitis models.
• Reference control for β-lactamase stability and carbapenemase detection assays.

APExBIO’s Meropenem trihydrate (B1217) supports reproducible workflows for advanced infection research. For detailed protocol guidance and troubleshooting, see "Meropenem Trihydrate: Carbapenem Antibiotic for Resistance…". This article clarifies the scope of metabolomics-driven advantages and solubility parameters.

Common Pitfalls or Misconceptions

• Meropenem trihydrate is not active against all carbapenem-resistant organisms; CPE strains with potent carbapenemases (e.g., KPC, NDM) may remain resistant (Dixon et al. 2025).
• Storage at room temperature or prolonged solution storage reduces compound stability; always store at -20°C and use freshly prepared solutions.
• It is not intended for clinical or diagnostic use; research use only as specified by APExBIO.
• Solubility in ethanol is negligible; use water or DMSO as solvents for laboratory applications.
• Incorrect pH conditions (<5.5) may significantly reduce antibacterial activity.

For metabolomic insights and innovative research strategies, compare with "Meropenem Trihydrate: Metabolomic Insights and Innovation…". This article extends those findings with updated LC-MS/MS biomarker validation and practical handling advice.

Workflow Integration & Parameters

Meropenem trihydrate (SKU B1217) is supplied as a solid by APExBIO. It is soluble in water (≥20.7 mg/mL with gentle warming to ≤37°C) and DMSO (≥49.2 mg/mL). For optimal stability, store the compound at -20°C and prepare solutions immediately before use. Short-term use (within 24 hours) is recommended for aqueous solutions to ensure potency. The compound is insoluble in ethanol. For in vivo work, dosing protocols should be titrated based on the infection model and pathogen load. LC-MS/MS metabolomics workflows can leverage Meropenem trihydrate as a reference standard for CPE phenotyping, as shown by Dixon et al. (2025).

For broader applications in next-generation antibacterial research and resistance phenotyping, see "Meropenem Trihydrate in Next-Generation Antibacterial Research…". This article clarifies recent advances in translational study design and the integration of Meropenem trihydrate into complex infection models.

Conclusion & Outlook

Meropenem trihydrate remains a cornerstone for research in bacterial infection and resistance, offering high potency, broad-spectrum activity, and reliable solubility profiles. Its performance as a reference agent in metabolomics, resistance detection, and acute infection models is supported by robust LC-MS/MS biomarker evidence (Dixon et al. 2025). APExBIO’s B1217 product enables reproducible, advanced experimental workflows. Ongoing developments in rapid detection and resistance modeling will continue to rely on such validated research tools, with particular emphasis on integrating metabolomic signatures for diagnostic innovation.